A GAD1 inhibitor suppresses osteosarcoma growth through the Wnt/β-catenin signaling pathway

Area of Science:

• Oncology
• Neuroscience
• Biochemistry

Background:

• Glutamate decarboxylase 1 (GAD1) is a key enzyme in the GABAergic system, primarily found in the central nervous system.
• Aberrant GAD1 expression is implicated in promoting tumor cell growth across various cancers.
• The specific role of GAD1 in osteosarcoma (OS) development and progression was previously unclear.

Purpose of the Study:

• To investigate the expression status of GAD1 in osteosarcoma (OS) tissues.
• To evaluate the therapeutic potential of the GAD1 inhibitor, 3-mercaptopropionic acid (3-MPA), in OS.
• To elucidate the underlying molecular mechanisms by which 3-MPA affects OS growth.

Main Methods:

• Analysis of GAD1 expression in OS patient data (R2 database) and tissues (immunohistochemistry).
• In vitro assessment of 3-MPA's effects on OS cell viability, colony formation, and cell cycle.
• In vivo evaluation of 3-MPA's efficacy in a tumor-bearing nude mouse model.

Main Results:

• GAD1 expression was significantly upregulated in OS tissues compared to adjacent normal tissues.
• Western blotting confirmed elevated GAD1 levels in OS cells versus human osteoblast cells.
• 3-MPA demonstrated significant inhibition of OS cell growth both in vitro and in vivo.
• 3-MPA treatment led to the inhibition of β-catenin and cyclin D1, inactivating the Wnt/β-catenin pathway.

Conclusions:

• Osteosarcoma exhibits increased expression of the GABAergic marker GAD1.
• The GAD1 inhibitor 3-MPA effectively reduces osteosarcoma growth.
• Inhibition of the Wnt/β-catenin pathway is a key mechanism underlying 3-MPA's antitumor effects in OS.